Pfizer wins EU approval for MabThera biosimilar
The drug will be available to treat certain cancers and autoimmune conditions
Read Moreby Selina McKee | Apr 3, 2020 | News | 0
The drug will be available to treat certain cancers and autoimmune conditions
Read Moreby Selina McKee | Nov 5, 2018 | News | 0
Novartis group Sandoz has decided not to pursue US submission of a biosimilar version of Roche’s Rituxan/Mabthera, after a request from regulators for more data.
Read Moreby Selina McKee | Nov 1, 2018 | News | 0
Roche says a combination of Venclyxto and MabThera has been approved in the European Union for people with previously treated chronic lymphocytic leukaemia.
Read Moreby Selina McKee | Jul 10, 2018 | News | 0
A late-stage trial of Servier and CTI BioPharma’s Pixuvri in combination with Roche’s MabThera has failed to hit targets in B-cell non-Hodgkin lymphoma, putting its conditional approval in Europe in jeopardy.
Read Moreby Selina McKee | Jun 27, 2017 | News | 0
Novartis group Sandoz has launched two new biosimilars across the UK potentially expanding access to biologic treatments for a range of inflammatory conditions and blood cancers.
Read Moreby Selina McKee | Jun 19, 2017 | News | 0
Novartis is poised to turn up the pressure on sales of Roche’s monoclonal antibody MabThera/Rituxan after EU regulators approved its cheaper biosimilar version of the mega blockbuster for use across blood malignancies and immunological diseases.
Read Moreby Selina McKee | Feb 23, 2017 | News | 0
Mundipharma is gearing up to launch biosimilar Truxima in seven European markets for the treatment of certain cancers and inflammatory conditions, after Celltrion bagged a regulatory approval for the drug.
Read Moreby Selina McKee | May 24, 2016 | News | 0
European regulators have agreed to review Sandoz’ biosimilar to Roche’s oncology/immunology blockbuster rituximab.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
